Authors, reviewers and readers may want to know about potential conflicts of interest that may arise with journal editors in the processing of submissions. Journal policy precludes editors from serving as the assigned editor on any paper on which they appear as an author. In general, editors will not serve as the assigned editor for submissions arising from within their own institution, although there may be exceptions to this if there is no clear association of the editor and author or their respective departments. Editors are also asked to excuse themselves from assignments where they have a personal conflict which might preclude conducting a fair and impartial review process. In addition to these general principals, listed below is specific financial information for each of the journal editors covering the past three years. Editors will also excuse themselves for submissions where conflicts exist regarding these outside financial interests, if any.
Robert L. Balster is the Butler Professor of Pharmacology and Toxicology, Research Professor of Psychology and Director of the Institute for Drug and Alcohol Studies at Virginia Commonwealth University in Richmond, Virginia USA. His current academic salary is provided in part by Virginia Commonwealth University, research grants from the National Institute on Drug Abuse for which he serves as a principal investigator, co-investigator or consultant, a contract from the Virginia Tobacco Settlement Foundation (a nonprofit entity established to administer a portion of the funds from the Master Tobacco Settlement Agreement), a contract from the U.S. Department of State for directing of the Humphrey Fellowship Program in Substance Abuse Prevention and Treatment and the Luther A. Butler Fund in the Medical College of Virginia Foundation. Dr. Balster receives outside income from editing, consulting and lectureships. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Balster for his efforts as Editor-in-Chief of the journal. This honorarium is increased for additional duties in the processing of supplemental issues of the journal. The publisher also provides some funds to cover editorial expenses in the journal office. Consulting also results in outside income. Over the past three years, Dr. Balster has consulted and/or received consulting fees from the following companies (either directly or indirectly): Abbott Laboratories, Alcologix, Alpharma, Astra Zeneca, Eisai, Johnson and Johnson, Jurox, Global Biodevelopment, Pfizer, Servier, Shionogi, TAP Pharmaceuticals and the Consumer Healthcare Products Association. Dr. Balster has also received honoraria for scientific talks and lectures at various meetings and universities and for grant and contract proposal review for the National Institutes of Health and for preparing a background document on tobacco control for the WHO. Virginia Commonwealth University and the departments and institute in which Dr. Balster works receives sponsored program support for research and training from a large number of sources. The Institute for Drug and Alcohol Studies is the recipient of support for graduate scholarships from Reckitt-Benckiser Pharmaceuticals, with headquarters in Richmond, Virginia. Dr. Balster has no current investments in pharmaceutical, tobacco, alcohol beverage or other firms with entrepreneurial activities pertinent to his service as associate editor aside from possible inclusion in mutual funds over which he has no control as an individual investor. (updated July, 2009)
Chris-Ellyn Johanson is a Professor in the Departments of Psychiatry and Behavioral Neurosciences and Psychology at Wayne State University (WSU), Associate Director of Substance Abuse Research Division in the former department, and Co-Director of the Psychiatric and Addiction Research Center inpatient unit. Her academic salary is provided in part by WSU-SOM, research grants from the National Institute on Drug Abuse for which she serves as a principal investigator or co-investigator, and Joe Young, Sr funds from the State of Michigan. She will be leaving this position September 30, 2006 and will take a position at that time in the Department of Psychiatry at Loyola University Chicago Stritch School of Medicine from which her academic salary will be paid. Elsevier, the owner and publisher of Drug and Alcohol Dependence, provides an honorarium to Dr. Johanson for her efforts as Associate Editor of the journal. Dr. Johanson is married to Charles R. Schuster, a colleague in the field. Both Dr. Johanson and Dr. Schuster receive honoraria for scientific talks and lectures at various universities and for grant proposal reviews for the National Institutes of Health and Veterans Administration. Consulting also results in outside income for both of them and is paid directly to CRS Associates, LLC. Over the past three years, the following pharmaceutical companies have provided consulting fees or directly funded research: Abbott, Alza, Boehringer-Ingelheim, Forest, GlaxoSmithKline, McNeil, New River, Ovation, Pfizer, Reckett-Benckiser, and Shire. Dr. Johanson and Dr. Schuster have no current investments in pharmaceutical, tobacco, alcohol beverage or other firms with entrepreneurial activities pertinent to her service as Associate Editor aside from possible inclusion in mutual funds over which they have has no control as individual investors. (updated May 2006)
Eric C. Strain is a Professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. His academic salary is provided by grants from the National Institute on Drug Abuse, as well as funds from Johns Hopkins University. Dr. Strain is a current and past recipient of NIDA research grants. Each year he receives honoraria for his services on behalf of the federal government (e.g., grant reviews) and from academic medical centers (e.g., providing grand rounds). He also receives a modest royalty from textbooks he has co-edited. In addition, in the past three years he has received outside income by providing consulting and speaking services to pharmaceutical companies, other related health service companies, and expert work on forensic cases. In the past three years he has provided consulting and speaking services to pharmaceutical companies (Abbott Laboratories, Grunenthal, Reckitt-Benckiser, Schering-Plough, Shire Pharmaceuticals, Titan Pharmaceuticals), he has received meals provided by a pharmaceutical company (Reckitt-Benckiser), consulted for other related health service companies (Pinney Associates, The Oak Group, Friends Research Institute), and served as an expert reviewer of forensic cases (with reimbursement for these services by local and national law firms associated with these cases). Dr. Strain's family has small equity holdings in companies with prominent sales of caffeine-containing beverages, and in one pharmaceutical company (Gilead Sciences). Dr. Strain currently has no other investments in pharmaceutical, tobacco, or alcohol beverage or other firms with entrepreneurial activities pertinent to his service as associate editor aside from possible inclusion in mutual funds over which he has no control as an individual investor. He receives an honorarium from Elsevier for his services as Associate Editor of Drug and Alcohol Dependence. (Updated July of 2009)
Steffanie A. Strathdee is Professor, Harold Simon Chair and Chief of the Division of International Health and Cross Cultural Medicine in the Department of Family and Preventive Medicine at the University of California, San Diego School of Medicine. She is also an Adjunct Professor in the Department of Epidemiology at Johns Hopkins University. Her salary support is provided in part from the University of California and research grants from the National Institute of Health, particularly the National Institute on Drug Abuse. Conflicts of interests exist by virtue of her research collaborations and co-funding with certain faculty members at the Johns Hopkins School of Public Health and the University of British Columbia. Dr. Strathdee periodically receives honoraria for chairing the Scientific Review Committee of the Ontario HIV Treatment Network, lectures on research topics related to HIV and drug abuse and grant proposal reviews for the National Institutes of Health. Currently or in the past, Dr. Strathdee has had no investments in pharmaceutical, tobacco, alcohol beverage or other firms with entrepreneurial activities. She receives an honorarium from Elsevier for her service as Associate Editor of Drug and Alcohol Dependence. (updated August, 2005)
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company